Nektar Therapeutics Reports Pfizer Inc. Announcement Of New Exubera Data

Nektar Therapeutics (Nasdaq:NKTR - News) today reported results announced by Pfizer Inc from two ongoing studies that showed adults with type 1 or type 2 diabetes treated with Exubera® (insulin human (rDNA origin)) Inhalation Powder experienced sustained blood sugar control over a two-year period and gained about half as much weight as those taking injected insulin. These data were presented today at the 66th Annual Scientific Sessions of the American Diabetes Association.

Back to news